Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
出版年份 2019 全文链接
标题
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HEART FAILURE
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-09-16
DOI
10.1002/ejhf.1596
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program
- (2019) Gemma A. Figtree et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leptin-Aldosterone-Neprilysin Axis
- (2018) Milton Packer CIRCULATION
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis
- (2018) Milton Packer DIABETES OBESITY & METABOLISM
- Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium
- (2018) Milton Packer JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction
- (2018) Walter J. Paulus et al. JACC-Heart Failure
- Obesity-Related Heart Failure With a Preserved Ejection Fraction
- (2018) Milton Packer et al. JACC-Heart Failure
- Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
- (2018) Annayya R. Aroor et al. Cardiovascular Diabetology
- The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Epicardial fat in heart failure patients with mid-range and preserved ejection fraction
- (2018) Gijs van Woerden et al. EUROPEAN JOURNAL OF HEART FAILURE
- Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction
- (2018) Jasper Tromp et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor–dependent pathway after renal injury in mice
- (2018) Yifan Zhang et al. KIDNEY INTERNATIONAL
- Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
- (2018) Fumitaka Soga et al. Cardiovascular Diabetology
- Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes
- (2018) Jesper Jensen et al. DIABETES OBESITY & METABOLISM
- The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range
- (2018) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
- (2018) Laween Uthman et al. Frontiers in Physiology
- The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors
- (2017) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease
- (2017) Vaibhav B. Patel et al. HEART FAILURE REVIEWS
- Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure
- (2017) Milton Packer et al. LANCET
- Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
- (2017) Shusuke Yagi et al. Diabetology & Metabolic Syndrome
- Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
- (2017) Jasper Tromp et al. Journal of the American Heart Association
- Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction
- (2017) Scott D. Solomon et al. JACC-Heart Failure
- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
- (2017) Tatsuya Fukuda et al. Diabetes Therapy
- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
- (2017) Tatsuya Fukuda et al. Diabetes Therapy
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
- (2016) Hiroaki Kusaka et al. Cardiovascular Diabetology
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Central obesity associates with renal hyperfiltration in the non-diabetic general population: a cross-sectional study
- (2016) Vidar Tor Nyborg Stefansson et al. BMC Nephrology
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
- (2014) David ZI Cherney et al. Cardiovascular Diabetology
- Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction
- (2013) Muaz M. Abudiab et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
- (2013) Frank Edelmann et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure With Preserved Ejection Fraction
- (2012) Selma F. Mohammed et al. Circulation-Heart Failure
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
- (2012) Scott D Solomon et al. LANCET
- Obesity and Diabetic Kidney Disease
- (2012) Christine Maric-Bilkan MEDICAL CLINICS OF NORTH AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now